Over the last years, although considerable efforts have been made in the treatment of HER2+ breast cancer, the emergence of resistance mechanisms to HER2‐targeted therapies, as well as their adverse effects stressed the need for the identification of new drugs acting on mutated and truncated forms of the receptor. Here, ERBB2 is linked to breast cancer.